Advances in Cancer Research
Series: Advances in Cancer Research; 142;
- Publisher's listprice EUR 122.00
-
50 599 Ft (48 190 Ft + 5% VAT)
The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.
- Discount 10% (cc. 5 060 Ft off)
- Discounted price 45 540 Ft (43 371 Ft + 5% VAT)
Subcribe now and take benefit of a favourable price.
Subscribe
50 599 Ft
Availability
printed on demand
Why don't you give exact delivery time?
Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.
Product details:
- Publisher Elsevier Science
- Date of Publication 18 March 2019
- ISBN 9780128171530
- Binding Hardback
- No. of pages217 pages
- Size 229x152 mm
- Weight 480 g
- Language English 0
Categories
Long description:
Advances in Cancer Research, Volume 142, the latest release in this ongoing, well-regarded serial, provides invaluable information on the exciting and fast-moving field of cancer research.
MoreTable of Contents:
1. Highly variant DNA methylation in normal tissues identifies a distinct subclass of cancer patientsJayashri Ghosh, Bryant Schultz, Christos Coutifaris and Carmen Sapienza2. Bittersweet tumor development and progression: Emerging roles of epithelial plasticity glycosylationsRyan M. Phillips, Christine Lam, Hailun Wang and Phuoc T. Tran3. The second genome: Effects of the mitochondrial genome on cancer progressionAdam D. Scheid, Thomas C. Beadnell and Danny R. Welch4. Pathways- and epigenetic-based assessment of relative immune infiltration in various types of solid tumorsManny D. Bacolod, Francis Barany, Karsten Pilones, Paul B. Fisher and Romulo J. de Castro5. HVEM network signaling in cancerJohn R. Sedï¿1⁄2 and Parham Ramezani-Rad6. Pharmacology of ME-344, a novel cytotoxic isoflavoneLeilei Zhang, Jie Zhang, Zhiwei Ye, Danyelle M. Townsend and Kenneth D. Tew
More
